产品信息
| 别名 | Interleukin 35; IL35; hIL35 |
| 物种 | Human |
| 表达宿主 | Human Cells |
| 序列信息 | asd |
| 检索号 | Q14213&P29459 |
| 分子量 | 73.9 kDa |
| 表观分子量 | 90-120 kDa |
| 标签 | C-6His |
| 生物活性 | Measured by its ability to bind biotinylated human IL6RB-Fch in a functional ELISA. |
产品特性
| 纯度 | >80% as determined by reducing SDS-PAGE. |
| 内毒素 | < 1.0 EU per µg as determined by LAL test. |
| 保存 | Lyophilized protein should be stored at -5~-20℃, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at -5~-20℃ for 3 months. |
| 运输 | Ambient temperature or ice pack. |
| 制剂 | Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
| 复融 | Please refer to it for detailed information. |
背景介绍
The novel Ebi3-IL-12alpha heterodimeric Cytokine has been designated Interleukin-35 (IL-35), is a member IL12 family Cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric Protein composed of IL-12α (P35) and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory Cytokine that may be specifically produced by T (reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4 (+)CD25 (+)Foxp3 (+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory Cytokine, along with TGFbeta Cytokine. IL-35 is a Cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory Cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.
